MDXG Split History

MiMedx Group (MDXG) has 1 split in our MDXG split history database. The split for MDXG took place on April 02, 2008. This was a 3235 for 10000 reverse split, meaning for each 10000 shares of MDXG owned pre-split, the shareholder now owned 3235 shares. For example, a 1000 share position pre-split, became a 323.5 share position following the split.

When a company such as MiMedx Group conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the MDXG split history from start to finish, an original position size of 1000 shares would have turned into 323.5 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into MiMedx Group shares, starting with a $10,000 purchase of MDXG, presented on a split-history-adjusted basis factoring in the complete MDXG split history.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	08/14/2012
End date:	08/11/2022
Start price/share:	$2.26
End price/share:	$4.00
Dividends collected/share:	$0.00
Total return:	76.99%
Average Annual Total Return:	5.88%
Starting investment:	$10,000.00
Ending investment:	$17,704.00
Years:	10.00

About MiMedx Group

MiMedx Group is a wound care and a therapeutic biologics company, developing and distributing placental tissue allografts. Co. provides products in the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Co.'s biomaterial platform technologies include AmnioFix®, EpiFix®, EpiCord®, AmnioCord® and AmnioFill®. AmnioFix and EpiFix are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. EpiCord and AmnioCord are tissue allografts derived from umbilical cord tissue. AmnioFill is a placental connective tissue matrix, derived from the placental disc and other placental tissue. According to our MDXG split history records, MiMedx Group has had 1 split.